Ajinomoto's $546M Acquisition of US-based Forge Biologics
jason tuinstra 4OfaTz6SdYs unsplash

Japan’s Ajinomoto agreed to acquire U.S.-based genetic medicines maker Forge Biologics Holdings for 82.8 billion yen ($546 million).

The transaction is expected to be completed in December 2023 pending regulatory approvals, Ajinomoto said a release.

Ajinomoto, whose primary business is in seasonings and processed foods, has a healthcare segment that focuses on drugs derived from amino acids.

Forge, based in the U.S. state of Ohio, is a contract development and manufacturing organization (CDMO) for gene-based therapies. Ajinomoto said Forge will integrate with its own AminoScience platform to work on new treatment options for rare diseases.

($1 = 151.7400 yen)

Source: Reuters

Related Articles

General
Information, News
A high-rise hotel with upper levels made of wood has opened in Sapporo, and operator Mitsubishi Estate Co. said most of the lumber used to construct the 11-story building was sourced from Hokkaido.
General, Investors/Business
Information
You want to profit from the weaker yen and invest in Japan, but don't know where to start? Before diving into the market here, you’ll need a general investment strategy, something that will help you decide on where, how, and what to invest in! For those that have never stepped foot into the country, it may seem like an extra challenge with finding the best locations and criteria. Let’s break it down to make better sense of it... Follow these rules!
General
News
One would think that with Covid-19 and between people keen on running away from major urban centres to get away from crowds, and Japan’s aging demographics, the residential property market would take a hit. No so! In fact, just the opposite. Institutional investors have, in fact, been pouring funds into portfolios.